SEP 08, 2017 1:46 PM PDT

Lipoxin: A New Drug for Heart Attack Recovery

WRITTEN BY: Kara Marker

More than half of all heart attack patients die within five years of the event. This is a frightening statistic, but University of Alabama at Birmingham scientists are focused on making that number smaller and making lives longer. In their most recent study, published in the journal Scientific Reports, researchers boost post-heart attack healing with a molecule called lipoxin.

According to the American Heart Association, cardiovascular disease is the underlying cause of death for nearly 1 in every 3 deaths in the United States.

Lipoxins are right in the middle of the action when it comes to the immune system and have been used to treat inflammatory disorders, renal fibrosis, and even cancer because of it. They are known to be anti-inflammatory, making them the perfect candidate for reducing chronic inflammation following a heart attack.

The immune response following a heart attack isn’t inherently harmful. The first wave is an acute inflammatory response, where white blood cells flow into the heart tissues to remove dead cells and begin building scar tissue to replace them. After this, the immune response begins the healing process.

These two reactions are normal and healthy. But when the initial stage of acute inflammation turns into chronic inflammation, that’s a problem. Over time, excessive inflammation leads to swelling in the heart’s left ventricle, ultimately resulting in congestive heart failure and death.

But in the new University of Alabama at Birmingham study, researchers found that giving mice a form of lipoxin called 15-epimer lipoxin A4, also known as “aspirin-trigger lipoxin A4,” improved heart function after a heart attack by boosting activity during the healing phase but leaving the acute inflammation phase alone. With this effect, lipoxin reveals its therapeutic potential as a post-heart attack treatment.

The research team started by inducing heart attacks in mice models, followed by a treatment of lipoxin. To see how it worked to improve heart function, they took observed and measured the following:

  • Heart function and swelling in the lungs

  • Spleen and kidney function (These organs are also affected by the initial acute immune response during a heart attack)

  • Neutrophil clearance during the healing phase (Neutrophils are first-responders in the immune system)

  • Activation or inhibition of macrophage receptors (Macrophages engulf and digest dead and dying cells)

  • Changes in pro-resolving gene markers in the left ventricle, spleen and kidneys

  • Changes in interleukin levels (Certain interleukins indicate changes in the immune system)

  • Transition of fibroblasts into secretory myofibroblasts (Fibroblasts deposit collagen, contribution to scarring)

Analysis of these parameters led them to the final conclusion that lipoxin successfully boosts heart function after a heart attack. First, researchers saw an improved ejection fraction, a measurement of how much blood is pushed out of the heart when it contacts. The better the ejection fraction, the more oxygenated blood is sent out into the body to provide tissues with oxygen and nutrients.

In addition, researchers saw active receptors on reparative macrophages and inhibited receptors on inflammatory macrophages. Lipoxin increased the number of neutrophils pushing their way into the heart during acute inflammation, and it promoted the clearance of neutrophils and reparative macrophages during the healing phase.

All things considered, lipoxin has a powerful and beneficial effect on the heart at a time when recovery is extremely vital, for the short-term and for the long-term.

Sources: MayoClinic, Journal of Inflammatory Research, University of Alabama at Birmingham

About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
JAN 24, 2020
Immunology
JAN 24, 2020
Immune "Recycling" Could Improve Cancer Immunotherapy
A natural housekeeping function performed by many cells of the human body, including those in the immune system, is under intense scrutiny for its potentia...
FEB 07, 2020
Clinical & Molecular DX
FEB 07, 2020
New diagnostic technology uses levitating proteins
Intrinsic biophysical properties of proteins hold valuable clues about how they function and their role in disease. Take, for example, one of the most comm...
FEB 12, 2020
Microbiology
FEB 12, 2020
Using Genomics to Learn More About a Mumps Outbreak
Though vaccination rates are high, small mumps outbreaks sometimes still occur....
FEB 11, 2020
Cancer
FEB 11, 2020
Could we be over-diagnosing cancer?
Roughly one in every two people are estimated to receive a cancer diagnosis at some point in their lives, but are all of those diagnoses valid? New researc...
FEB 17, 2020
Neuroscience
FEB 17, 2020
Being Bilingual Accelerates Alzheimer's Disease in the Brain
Although knowing two languages may be able to delay the onset of Alzheimer’s, researchers from Canada’s York University have found that it may ...
FEB 21, 2020
Clinical & Molecular DX
FEB 21, 2020
Diagnosing COVID-19
Diagnosing coronavirus is done through next-generation sequencing, real-time RT-PCR tests, cell culture, and electron miscopy. For patients, that translate...
Loading Comments...